300363 Porton Pharma Solutions
- 17.64
- -0.37-2.05%
Porton Pharma Solutions News
Express News | Porton Pharma Solutions: The overseas market has seen a significant improvement in both the volume of inquiries and customer development compared to previous years.
Porton Pharma Solutions (300363): Order growth drives revenue improvement, with losses narrowing slightly.
Items: In Q3, the company achieved revenue of 0.773 billion yuan (+10.73%). Achieved a net income attributable to the parent company of -0.036 billion yuan (-187.72%), and after deducting non-recurring items, the net income attributable to the parent company was -0.039 billion yuan (-211.
Express News | CRO sector fluctuated and rebounded, porton pharma solutions rose more than 15%.
Boteng shares: 2024 third quarter report
Express News | Porton Pharma Solutions and Yinosi have reached a global strategic cooperation.
Porton Pharma Solutions (300363.SZ): The net loss in the third quarter was 36.3932 million yuan.
Porton Pharma Solutions (300363.SZ) released its third-quarter report on October 24th. In the third quarter of 2024, the company achieved revenue of 0.773 billion yuan, a year-on-year increase of 10.73%; net income attributable to shareholders of the listed company was a loss of 36.3932 million yuan, a year-on-year decrease of 187.72%; net income loss after deducting non-recurring gains and losses was 39.393 million yuan, a year-on-year decrease of 211.61%; basic earnings per share were a loss of 0.07 yuan/share.
Porton Pharma Solutions (300363.SZ) released its performance for the first three quarters, with a net loss of 0.206 billion yuan.
Porton Pharma Solutions (300363.SZ) released the third quarter report for 2024, with revenue of 21...
Porton Pharma Solutions (300363): Significant improvement in revenue on a month-on-month basis. Orders and profitability continue to show marginal improvement.
Event Overview The company announced its 2024 third quarter report: In the first three quarters of 2024, it achieved revenue of 2.125 billion yuan, a year-on-year decrease of 30.02%, and achieved net income attributable to the parent company of -0.206 billion yuan, a year-on-year decrease of 145.68%.
Express News | Boteng Biology and Microgene have reached a strategic cooperation.
Porton Pharma Solutions (300363): Quarterly losses narrowed down, steady progress in emerging businesses.
Event: Porton Pharma Solutions released its 2024 interim report. The company achieved revenues of 1.352 billion yuan in the first half of 2024 (a decrease of 42.19% YoY); net income attributable to the parent company was -0.17 billion yuan (a decrease of 141.43% YoY); after deducting ...
Porton Pharma Solutions (300363): The profit margin improved compared to the previous quarter, looking forward to order conversion.
The performance in the first half of the year was slightly lower than our expectations. The company announced the performance for the first half of the year: revenue of 1.352 billion yuan, a year-on-year decrease of 42.19%, excluding substantial orders, the year-on-year decrease was about 4%; net loss attributable to shareholders of 0.17 billion yuan; non-recurring net loss of 1.7 billion yuan.
Boteng shares: 2024 semi-annual report
Boteng Shares: 2024 Semi-Annual Report Summary
Porton Pharma Solutions (300363.SZ) released its semi-annual performance, with a net loss of 0.17 billion yuan, a year-on-year reversal from profit to loss.
Porton Pharma Solutions (300363.SZ) disclosed the semi-annual report for the first half of 2024. In the reporting period, the company achieved revenue of 1 million yuan...
Porton Pharma Solutions (300363.SZ): Net loss of 0.17 billion yuan in the first half of the year, turning from profit to loss year-on-year.
Porton Pharma Solutions (300363.SZ) announced its 2024 interim report on August 27th. During the reporting period, the revenue was 1.352 billion yuan, a decrease of 42.19% year-on-year; the net income attributable to shareholders of the listed company was -0.17 billion yuan, turning from profit to loss year-on-year; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -0.174 billion yuan; and the basic earnings per share was -0.31 yuan.
Express News | BoTeng Biology and Gese Biology have reached a global strategy cooperation to jointly promote innovative circRNA therapies.
Porton Pharma Solutions' Factory Passes US FDA Inspection
Express News | Porton Pharma Solutions: Chongqing Changshou factory passes on-site inspection by the US FDA.
Express News | Porton Pharma Solutions: Some executives plan to collectively increase their shareholding of the company's shares by 6 to 10 million yuan.
Two executives of Porton Pharma Solutions (300363.SZ) plan to spend between 0.6 million yuan and 1 million yuan to increase their shareholdings.
Porton Pharma Solutions (300363.SZ) announced that Chen Hui, deputy general manager and financial officer of the company, and the deputy general manager and director...
Analysis
Price Target
No Data
No Data